<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=348185225613720&amp;ev=PageView&amp;noscript=1">
Skip to content

GENEWIZ WEEK 2024 WORKSHOP

Accelerating Antibody-Drug Conjugate (ADC) Discovery with High-Throughput rAb Screening

On-Demand Webinar
 
 
GWeek24_Workshops_LP-Laptop-Graphic@3x

About the workshop

Given their highly effective nature and simple design, antibody-drug conjugates (ADCs) are a rapidly growing class of therapeutics, particularly for oncology, with over 100 currently in clinical trials. However, selecting high-performing antibody candidates early in the discovery process is crucial to increase the chance of antibody program success. During the workshop, we will explore robust, high-throughout recombinant antibody (rAb) tools using machine learning for screening hundreds to thousands of candidates in parallel to identify new, effective antibody candidates.

 

What you'll learn about

  • ADCs as an emerging option for therapeutic antibodies
  • Advantages of high-throughput rAb production using machine learning
  • Techniques used to enhance antibody expression (optimization, expression systems, purification strategies, etc.)

About the presenter

CrystalRichardson_500x500px

Crystal Richardson, Ph.D.

Senior Business Partnership Manager, Azenta Life Sciences

Dr. Crystal Richardson earned her Ph.D. from the University of Virginia with a degree in biomedical sciences. She has over six years of experience in molecular biology with a focus on clinical immunology. At Azenta, Dr. Richardson supports business operations and is our subject matter expert for adeno-associated virus (AAV) and recombinant antibody production.

Watch now